{rfName}
Ec

Indexed in

License and Use

Icono OpenAccess

Altmetrics

Analysis of institutional authors

Ramirez Mahaluf, Juan PabloAuthorCanete, J DCorresponding AuthorCelis, RAuthorSanmarti, RAuthorRamirez, JAuthor

Share

November 6, 2015
Publications
>
Article

Ectopic lymphoid neogenesis is strongly associated with activation of the IL-23 pathway in rheumatoid synovitis

Publicated to: Arthritis Research & Therapy. 17 (173): 173- - 2015-07-09 17(173), DOI: 10.1186/s13075-015-0688-0

Authors:

Canete, Juan D; Celis, Raquel; Yeremenko, Nataliya; Sanmart, Raimon; van Duivenvoorde, Leonie; Ramirez, Julio; Blijdorp, Iris; Garcia-Herrero, Carmen M; Pablos, Jose L; Baeten, Dominique L
[+]

Affiliations

Amsterdam Rheumatology and Immunology Center/Department of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands - Author
Arthritis Unit, Rheumatology Department, Hospital Clinic of Barcelona and IDIBAPS, c/ Villarroel, 170, 08036, Barcelona, Spain - Author
Rheumatology Department, Instituto de Investigacion Hospital 12 de Octubre (I + 12), Avda de Cordoba, s/n, 28041, Madrid, Spain - Author
Arthritis Unit, Rheumatology Department, Hospital Clinic of Barcelona and IDIBAPS, c/ Villarroel, 170, 08036, Barcelona, Spain - Author
Hosp Clin Barcelona, Dept Rheumatol, Arthritis Unit, E-08036 Barcelona, Spain - Author
IDIBAPS, Barcelona 08036, Spain - Author
Inst Invest Hosp 12 Octubre 1 12, Dept Rheumatol, Madrid 28041, Spain - Author
UB - Author
Univ Amsterdam, Acad Med Ctr, Amsterdam Rheumatol & Immunol Ctr, Dept Clin Immunol & Rheumatol, NL-1105 AZ Amsterdam, Netherlands - Author
See more

Abstract

The functional relevance of synovial ectopic lymphoid neogenesis (ELN) in rheumatoid arthritis (RA) remains unknown. As ELN correlates with the degree of tissue inflammation, we investigated whether ELN was associated with specific cytokine profiles.Synovial ELN was determined by immunohistology and long CD21 isoform (CD21L) expression. Cytokine expression was determined by multiplex enzyme-linked immunosorbent assay (ELISA) and quantitative polymerase chain reaction (PCR) as well as immunohistology in synovial fluid (SF) (n?=?44) and tissue (ST) (n?=?108), respectively. Production of ELN-associated chemokines by fibroblast-like synoviocytes (FLS) was studied in vitro.Screening analysis of SF by multiplex ELISA showed higher protein levels of interleukin (IL)-23 (p?=?0.018) and IL-17F (p?=?0.028) in ELN+ versus ELN- samples. Other cytokines, including IL-17A, IL-6, and tumor necrosis factor (TNF)-?, were not different. The association between IL-23 and ELN was not biased by disease activity or other clinical features and was confirmed by higher IL-23 mRNA expression in ELN+ versus ELN- ST samples (p?=?0.030), a correlation between IL-23 and CD21L expression in the same samples (r?=?0.70 p? [+]

Keywords

arthritisb-cellsccl21double-blindexpressioninduceinterleukin-17mast-cellsorganizationAgedArthritis, rheumatoidCell recruitmentChoristomaEnzyme-linked immunosorbent assayFemaleHumansIl17f protein, humanImmunohistochemistryInterleukin-17Interleukin-23Lymphoid tissueMaleMiddle agedReal-time polymerase chain reactionSynovial membraneSynovitis

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Arthritis Research & Therapy due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2015, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category Immunology and Allergy.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 1.34. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 13, 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2026-01-31, the following number of citations:

  • WoS: 49
  • Scopus: 36
  • Europe PMC: 32
[+]

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2026-01-31:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 65.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 65 (PlumX).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
[+]

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Netherlands.

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Cañete Crespillo, Juan de Dios) .

the author responsible for correspondence tasks has been Cañete Crespillo, Juan de Dios.

[+]

Awards linked to the item

Funding: JDC was supported by grants PI11/1890 and RD08/0075/006 (Red de Investigacion en Inflamacion y Enfermedades Reumaticas, RIER), Instituto de Salud Carlos III (Spain, Cofinanced by FEDER, European Union). JLP was supported by grant PI 12/00439. DB, NY and LvD are supported by grants from the Dutch Arthritis Foundation (Reumafonds). DB is supported by the Dutch Science Foundation (NWO-VICI) and by the Innovative Medicines Initiative Be The Cure Joint Undertaking program (grant number 115142-2).
[+]